About Pliant Therapeutics, Inc.
https://pliantrx.comPliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
CEO
Bernard Coulie
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Piper Sandler
Overweight
Wells Fargo
Equal Weight
Leerink Partners
Market Perform
RBC Capital
Sector Perform
HC Wainwright & Co.
Neutral
Citigroup
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:6M
Value:$7.86M
BLACKROCK INC.
Shares:4.97M
Value:$6.51M
WOODLINE PARTNERS LP
Shares:4.5M
Value:$5.9M
Summary
Showing Top 3 of 119
About Pliant Therapeutics, Inc.
https://pliantrx.comPliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $28.27M ▼ | $-26.3M ▲ | 0% | $-0.43 ▲ | $-23.08M ▲ |
| Q2-2025 | $0 | $45.15M ▼ | $-43.3M ▲ | 0% | $-0.71 ▲ | $-42.04M ▲ |
| Q1-2025 | $0 | $58.94M ▲ | $-56.17M ▼ | 0% | $-0.92 ▼ | $-54.92M ▼ |
| Q4-2024 | $0 | $53.32M ▼ | $-49.73M ▲ | 0% | $-0.82 ▲ | $-48.44M ▲ |
| Q3-2024 | $0 | $62.01M | $-57.76M | 0% | $-0.95 | $-56.35M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $241.8M ▼ | $276.6M ▼ | $76.29M ▼ | $200.31M ▼ |
| Q2-2025 | $262.87M ▼ | $299.82M ▼ | $79.74M ▼ | $220.08M ▼ |
| Q1-2025 | $305.64M ▼ | $344.77M ▼ | $87.61M ▼ | $257.16M ▼ |
| Q4-2024 | $355.72M ▼ | $396.95M ▼ | $92.87M ▼ | $304.08M ▼ |
| Q3-2024 | $404.51M | $445.67M | $99.84M | $345.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-26.3M ▲ | $-21.08M ▲ | $27.92M ▼ | $72K ▲ | $6.91M ▲ | $-21.08M ▲ |
| Q2-2025 | $-43.3M ▲ | $-40.6M ▲ | $35.49M ▼ | $0 ▼ | $-5.12M ▼ | $-40.72M ▲ |
| Q1-2025 | $-56.17M ▼ | $-48.86M ▼ | $69.11M ▲ | $498K ▲ | $20.75M ▲ | $-49.13M ▼ |
| Q4-2024 | $-49.73M ▲ | $-47.66M ▼ | $39.13M ▲ | $102K ▼ | $-8.43M ▼ | $-47.87M ▼ |
| Q3-2024 | $-57.76M | $-32.27M | $30.96M | $543K | $-770K | $-33.17M |
CEO
Bernard Coulie
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Piper Sandler
Overweight
Wells Fargo
Equal Weight
Leerink Partners
Market Perform
RBC Capital
Sector Perform
HC Wainwright & Co.
Neutral
Citigroup
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:6M
Value:$7.86M
BLACKROCK INC.
Shares:4.97M
Value:$6.51M
WOODLINE PARTNERS LP
Shares:4.5M
Value:$5.9M
Summary
Showing Top 3 of 119